FRM
ESPR

Fox Run Management’s Esperion Therapeutics ESPR Stock Holding History

Fox Run Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,774
Closed -$85.8K – 738
2022
Q4 		$85.8K Buy
+13,774
New +$98.5K 0.03% 571
2017
Q4 		– Sell
-12,700
Closed -$637K – 729
2017
Q3 		$637K Buy
+12,700
New +$612K 0.18% 200
2016
Q3 		– Sell
-29,300
Closed -$289K – 543
2016
Q2 		$289K Buy
+29,300
New +$486K 0.14% 299

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Fox Run Management's ESPR Position: Q1 2023 in Review

Fox Run Management sold out of Esperion Therapeutics (ESPR) in Q1 2023, closing a stake of 13,774 shares — an estimated $85.8K sold.

Fox Run Management first reported a position in ESPR in Q2 2016 and held it in 3 quarters. The position peaked at $637K in Q3 2017. 164 funds tracked by Wall St. Rank hold ESPR as of Q1 2023.

  • Fox Run Management reported no remaining Esperion Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Fox Run Management sold 13,774 Esperion Therapeutics shares in Q1 2023, an estimated $85.8K.
  • Fox Run Management first reported a position in Esperion Therapeutics in Q2 2016 and held it in 3 quarters.
  • Fox Run Management's Esperion Therapeutics position peaked at $637K in Q3 2017.
  • 164 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2023.

Based on Fox Run Management's 13F filing for Q1 2023, filed 12 May 2023.